The efficacy of non-antibiotic therapies in recurrent urinary tract infections
DOI: 10.22591/magyurol.2024.4.keszthelyim.220
Authors:
Keszthelyi Márton dr.1, Lőczi Lotti Lúcia dr.1, Keszthelyi Attila dr.2
1Semmelweis Egyetem, Szülészeti és Nőgyógyászati Klinika, Budapest (igazgató: Ács Nándor dr.)
2Semmelweis Egyetem, Urológiai Klinika, Budapest (igazgató: Nyirády Pétrer dr.)
Summary
Introduction: Urinary tract infections (UTIs), especially recurrent cases, predominantly affect women, significantly impairing their quality of life. Accurate diagnosis and targeted prevention are crucial for the management and prevention of recurrent infections.
Methods: Our review summarizes the latest literature and the European Association of Urology’s 2024 consensus guidelines on the prevention of recurrent urinary tract infections, focusing on non-antibiotic treatment options.
Results and discussion: The vaginal microbiome, particularly lactobacilli, plays a crucial role in preventing urinary tract infections. OM-89, which contains Escherichia coli bacterial lysates, has been demonstrated to be one of the most effective immunoactive prophylaxis treatments, significantly reducing the occurrence of recurrent UTIs. Additionally, other non-antibiotic approaches, such as D-mannose, lactobacillus-based probiotics, and topical estrogen therapy, also show promise, though their efficacy remains inconsistent.
Conclusions: Non-antibiotic prophylaxis, particularly OM-89, has proven to be an effective method for preventing recurrent urinary tract infections. Further research is needed to fully understand the efficacy of other preventive treatments.